A new study published in Anticancer Research concluded that breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease as women with low levels of this nutrient. The researchers performed a statistical analysis of five studies of 25-hydroxyvitamin D obtained at the time of the patients diagnosis and their followup for an average of nine years on 4,443 breast cancer patients. The researcher said “Vitamin D metabolites increase communication between cells by switching on a protein that blocks aggressive cell division. As long as vitamin D receptors are present tumor growth is prevented and kept from expanding its blood supply. Vitamin D receptors are not lost until a tumor is very advanced. This is the reason for better survival in patients whose vitamin D blood levels are high.”
Women in the high serum group had an average of 30 nanograms per milliliter (ng/ml) of 25-hydroxyvitamin D in their blood compared to an average of 17 ng/mg in the low group. In addition, the average level for breast cancer patients in the United States is 17ng/ml. Clinical trials to validate the findings were recommended as well as incorporating a safe dose of vitamin D as part of breast cancer care comparable to 4,000 International Units daily of vitamin D from food or supplements in order to reach a serum level of 50ng/ml.